SEC Form 4 · accession 0001179110-16-029221
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald G Payan
Officer — EVP, Pres. Discovery&Research · Director
Period of report
Aug 30, 2016
Accepted (ET)
Sep 1, 2016 · 6:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 30, 2016 | S | 5,303 | $4.0004 | D | 53,031 | I | By Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 1, 2016.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.000 to $4.002, inclusive.
- F3The Reporting Person is a Co-Trustee.